Dynavax Technologies Corporation (DVAX) Earning Somewhat Favorable Press Coverage, Study Shows

News headlines about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dynavax Technologies Corporation earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.6191107132033 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at $21.60 on Friday.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company’s quarterly revenue was down 68.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.90) earnings per share. analysts expect that Dynavax Technologies Corporation will post -1.74 earnings per share for the current year.

DVAX has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Monday, July 10th. Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies Corporation in a report on Friday, September 15th. They set an “overweight” rating and a $24.00 target price on the stock. Royal Bank Of Canada reissued a “buy” rating and set a $26.00 price target on shares of Dynavax Technologies Corporation in a research report on Friday, September 1st. Cowen and Company reissued an “outperform” rating and set a $45.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Finally, William Blair reissued an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.00.

ILLEGAL ACTIVITY NOTICE: “Dynavax Technologies Corporation (DVAX) Earning Somewhat Favorable Press Coverage, Study Shows” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/05/dynavax-technologies-corporation-dvax-earning-somewhat-favorable-press-coverage-study-shows.html.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Insider Buying and Selling by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

What are top analysts saying about Dynavax Technologies Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dynavax Technologies Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit